Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, L. Green, Monique Topp et al.|Nature Communications|2018Cited by 299
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analysesEun Young Kang, P. Mackenzie, Dane Cheasley et al.|Modern Pathology|2020Cited by 43
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nešić, Harold C. Sullivan, John J. Krais et al.|Molecular Cancer|2024Cited by 28
CN88 A phase II randomized trial of nurse led telehealth follow-up including patient reported outcomes using the MOST-S26 (measure of ovarian symptoms and treatment concerns) versus routine clinic based or telehealth follow-up, after completion of chemotherapy in patients with ovarian cancerPaul A. Cohen, M.L. Friedlander, Jim Codde et al.|Annals of Oncology|2025Cited by 0